Developing AI tools to assess and manage cardiovascular risk after pregnancy
Pregnancy complications such as preeclampsia and gestational diabetes can signal future cardiovascular risk. Connecting these warning signs with longer-term follow-up is a challenge for women and clinicians, particularly after childbirth when care can become fragmented.
Emaia Health is developing a digital platform for personalised cardiovascular prevention after pregnancy. It combines risk assessment for clinicians with patient guidance and follow-up tools, using clinical data, biomarkers and artificial intelligence.
What stands out about Emaia Health
Received Ekintzaile and Txekintek public support for early development; Ekintzaile supported its prototype, market study and business plan.
Selected for the 2026 BIND accelerator programme, working with healthcare group Keralty on its prevention model.
Formalised a technology collaboration with Vicomtech, its co-founding research centre and partner for platform development.
Co-founder Iván Macía holds a doctorate in computer engineering and leads Digital Health and Biomedical Technologies at Vicomtech.
Collaboration with Keralty includes a retrospective study of clinical data from women with obstetric complications to assess medical need and model feasibility.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.